Browsing Tag
Celgene
13 posts
Tonix Pharmaceuticals stock up over 20%: Can TNX-102 SL and TNX-1700 fuel a turnaround in 2025?
Tonix Pharmaceuticals surged 21% despite deep losses, as retail traders bet on TNX-102 SL’s FDA nod and cancer pipeline momentum. Read the full story.
Natco Pharma completes full US generic Revlimid lineup with new lenalidomide strengths
Natco Pharma and Teva Pharmaceuticals launch 2.5 mg and 20 mg generic lenalidomide in US, completing their Revlimid portfolio for multiple myeloma treatment.
Dr Reddy’s Labs announces limited volume US launch of Lenalidomide Capsules
Dr Reddy’s Laboratories said that it has launched two of six strengths of cancer medication Lenalidomide Capsules, a…
Natco Pharma launches PrNAT-LENALIDOMIDE Capsules in Canada
Natco Pharma Limited has announced the Canadian launch of PrNAT-LENALIDOMIDE Capsules, a generic version of Celgene Corporation’s cancer…
Zydus Cadila gets FDA approval for Revlimid generic Lenalidomide Capsules
Zydus Cadila said that the US Food and Drug Administration (FDA) has granted it tentative approval for Lenalidomide…
Sun Pharma to settle patent litigation with Celgene for generic Revlimid
Sun Pharmaceutical Industries (Sun Pharma) along with one of its fully-owned subsidiaries has reached an agreement with Celgene,…
Natco Pharma gets FDA approval for Lenalidomide Capsules
Natco Pharma has secured the final approval from the US Food and Drug Administration (FDA) of its abbreviated…
EC approves Reblozyl for transfusion-dependent anemia in adults
Bristol Myers Squibb and Acceleron Pharma have secured approval from the European Commission (EC) for their jointly developed…
Bristol-Myers Squibb wraps up $74bn acquisition of Celgene
Bristol-Myers Squibb has wrapped up its $74 billion acquisition of Celgene having got regulatory approval from all government…
FTC clears decks for Bristol-Myers Squibb acquisition of Celgene
Bristol-Myers Squibb acquisition of Celgene : US pharma giant Bristol-Myers Squibb said that the US Federal Trade Commission…